Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2016 | Pages:
100 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Medullary Thyroid Cancer - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Medullary Thyroid Cancer - Pipeline Review, H2 2016', provides an overview of the Medullary Thyroid Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Medullary Thyroid Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Medullary Thyroid Cancer and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Medullary Thyroid Cancer - The report reviews pipeline therapeutics for Medullary Thyroid Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Medullary Thyroid Cancer therapeutics and enlists all their major and minor projects - The report assesses Medullary Thyroid Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Medullary Thyroid Cancer Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Medullary Thyroid Cancer - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Medullary Thyroid Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Medullary Thyroid Cancer Overview 8 Therapeutics Development 9 Pipeline Products for Medullary Thyroid Cancer - Overview 9 Pipeline Products for Medullary Thyroid Cancer - Comparative Analysis 10 Medullary Thyroid Cancer - Therapeutics under Development by Companies 11 Medullary Thyroid Cancer - Therapeutics under Investigation by Universities/Institutes 12 Medullary Thyroid Cancer - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Early Stage Products 15 Medullary Thyroid Cancer - Products under Development by Companies 16 Medullary Thyroid Cancer - Products under Investigation by Universities/Institutes 17 Medullary Thyroid Cancer - Companies Involved in Therapeutics Development 18 AbbVie Inc 18 Advenchen Laboratories, LLC 19 Bayer AG 20 Boehringer Ingelheim GmbH 21 Celgene Corporation 22 Hutchison MediPharma Limited 23 Immunomedics, Inc. 24 Nerviano Medical Sciences S.r.l. 25 Novartis AG 26 Pfizer Inc. 27 Medullary Thyroid Cancer - Therapeutics Assessment 28 Assessment by Monotherapy Products 28 Assessment by Target 29 Assessment by Mechanism of Action 32 Assessment by Route of Administration 35 Assessment by Molecule Type 37 Drug Profiles 39 AL-3818 - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 CLM-29 - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 CLM-3 - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 CLM-94 - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 everolimus - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 GI-6207 - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 HMPL-012 - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 nintedanib - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 NMS-616 - Drug Profile 72 Product Description 72 Mechanism Of Action 72 R&D Progress 72 pasireotide - Drug Profile 73 Product Description 73 Mechanism Of Action 73 R&D Progress 73 regorafenib - Drug Profile 77 Product Description 77 Mechanism Of Action 77 R&D Progress 77 rovalpituzumab tesirine - Drug Profile 87 Product Description 87 Mechanism Of Action 87 R&D Progress 87 Small Molecule 1 to Inhibit RET Receptor Tyrosine Kinase for Medullary Thyroid Cancer - Drug Profile 89 Product Description 89 Mechanism Of Action 89 R&D Progress 89 Small Molecule to Inhibit RET Receptor Tyrosine Kinase for Medullary Thyroid Cancer - Drug Profile 90 Product Description 90 Mechanism Of Action 90 R&D Progress 90 SYN-001 - Drug Profile 91 Product Description 91 Mechanism Of Action 91 R&D Progress 91 temsirolimus - Drug Profile 92 Product Description 92 Mechanism Of Action 92 R&D Progress 92 TF-2 - Drug Profile 94 Product Description 94 Mechanism Of Action 94 R&D Progress 94 Medullary Thyroid Cancer - Dormant Projects 96 Medullary Thyroid Cancer - Discontinued Products 97 Medullary Thyroid Cancer - Product Development Milestones 98 Featured News & Press Releases 98 Apr 03, 2013: GlobeImmune Initiates Phase II Study Of New T Cell Stimulating Cancer Vaccine Targeting CEA In Patients With Metastatic Medullary Thyroid Cancer 98 Appendix 99 Methodology 99 Coverage 99 Secondary Research 99 Primary Research 99 Expert Panel Validation 99 Contact Us 99 Disclaimer 100
List of Tables
Number of Products under Development for Medullary Thyroid Cancer, H2 2016 9 Number of Products under Development for Medullary Thyroid Cancer - Comparative Analysis, H2 2016 10 Number of Products under Development by Companies, H2 2016 11 Number of Products under Investigation by Universities/Institutes, H2 2016 12 Comparative Analysis by Late Stage Development, H2 2016 13 Comparative Analysis by Clinical Stage Development, H2 2016 14 Comparative Analysis by Early Stage Development, H2 2016 15 Products under Development by Companies, H2 2016 16 Products under Investigation by Universities/Institutes, H2 2016 17 Medullary Thyroid Cancer - Pipeline by AbbVie Inc, H2 2016 18 Medullary Thyroid Cancer - Pipeline by Advenchen Laboratories, LLC, H2 2016 19 Medullary Thyroid Cancer - Pipeline by Bayer AG, H2 2016 20 Medullary Thyroid Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016 21 Medullary Thyroid Cancer - Pipeline by Celgene Corporation, H2 2016 22 Medullary Thyroid Cancer - Pipeline by Hutchison MediPharma Limited, H2 2016 23 Medullary Thyroid Cancer - Pipeline by Immunomedics, Inc., H2 2016 24 Medullary Thyroid Cancer - Pipeline by Nerviano Medical Sciences S.r.l., H2 2016 25 Medullary Thyroid Cancer - Pipeline by Novartis AG, H2 2016 26 Medullary Thyroid Cancer - Pipeline by Pfizer Inc., H2 2016 27 Assessment by Monotherapy Products, H2 2016 28 Number of Products by Stage and Target, H2 2016 30 Number of Products by Stage and Mechanism of Action, H2 2016 33 Number of Products by Stage and Route of Administration, H2 2016 36 Number of Products by Stage and Molecule Type, H2 2016 38 Medullary Thyroid Cancer - Dormant Projects, H2 2016 96 Medullary Thyroid Cancer - Discontinued Products, H2 2016 97
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
